lynparza - olaparib tablet, film coated
(Olaparib)Astrazeneca Pharmaceuticals Lp
Usage: Lynparza is a PARP inhibitor for adults with BRCA- or HRR-mutated cancers. Indicated for maintenance of ovarian cancer, adjuvant and metastatic breast cancer, maintenance of metastatic pancreatic cancer, and metastatic castration-resistant prostate cancer. Patient selection requires an FDA-approved companion diagnostic.